Rite Aid is expecting its EnvisionRx acquisition to increase the company’s annual revenues by as much as 17.7%, from $26.5 billion in fiscal 2015 to a projected range of between $30.7 billion and $31.2 billion.
How serious are Rite Aid’s leaders when they proclaim their determination to make the company a full-service, full-spectrum retail healthcare provider? Serious enough to buy RediClinic — which has operated walk-in healthcare clinics in roughly 30 H-E-B stores in Texas for much of the past decade — and serious enough to embark on an aggressive growth campaign that includes the clinic healthcare provider as a new Rite Aid subsidiary.
Rite Aid is back — and in a very big way. After years of toiling in the shadows of its fast-growing and better-capitalized rivals, the company has regained its footing and market momentum with a renewed vitality and a sharply defined focus on its mission as a community-driven health-and-wellness retailer.
Rite Aid in late June announced that Bryan Everett will join the company as EVP of store operations, effective Aug. 3. Everett will be responsible for all operations at the company’s nearly 4,600 chainwide stores and will report to Rite Aid’s president and COO Ken Martindale.
More and more, the success of any healthcare delivery model in the United States will depend on the ability of all members of a patient-care team — physicians, pharmacists, hospital systems and health plan payers included — to collaborate effectively on a longterm plan of care that’s focused on successful outcomes and disease prevention.
One of Rite Aid’s most farsighted innovations has been the creation of a unique store position, the wellness ambassador, whose primary focus is serving customers to help deliver a better in-store shopping experience.
A big part of the reason behind Rite Aid’s success is that the story has changed. It’s no longer about swimming upstream or playing defense. Today, it’s about creating a retail healthcare company and aggressively turning that dream into reality.
Congress, Medicare and industry stakeholders should strike the right balance to cut out fraud in the Medicare Part D drug program while preserving patient access to critical medications, the National Community Pharmacists Association stated in comments submitted in conjunction with a House Energy and Commerce subcommittee hearing Tuesday on the topic.
America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.